NATHAN FRANK, M.D., F.A.C.P.; JOHN A. STRAZZA JR., M.D.; JAMES T. HELSPER, M.D.
This content is PDF only. Please click on the PDF icon to access.
It is the purpose of this paper to report the clinical results obtained with a new vasodilator, 2-benzyl-4, 5-imidazoline hydrochloride (Priscoline), in the treatment of 22 patients with various types of peripheral vascular disorders. In the past few years several new drugs have been added to the therapeutic armamentarium of peripheral vascular disease; these are: diethyl ether, histidine and ascorbic acid, vitamin E, dibenamine, tetraethyl ammonium and Priscoline.2 We at the Jersey City Medical Center have had some experience with the last three drugs.
The use of diethyl ether was reported by Katz1 in 1946. He administered the drug in
FRANK N, STRAZZA JA, HELSPER JT. THE EFFECTS OF PRISCOL (2-BENZYL-4, 5-IMIDAZOLINE HYDROCHLORIDE) IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASES1. Ann Intern Med. ;35:19–38. doi: 10.7326/0003-4819-35-1-19
Download citation file:
Published: Ann Intern Med. 1951;35(1):19-38.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use